A woman born with almost no functional vision because of a genetic mutation has regained measurable sight after a single ...

CRISPR Therapeutics (NasdaqGM:CRSP) has come under pressure after a six day losing streak that cut the stock by about 18%, ...

CRISPR Therapeutics stock has delivered a decline of about 61% over the past five years, yet current valuation checks suggest ...

Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition succeeded in a Phase 3 trial, a landmark for gene editing. The treatment uses Nobel Prize-winning Crispr technology ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly reported positive Phase 1b data for VERVE-102, a ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. CRISPR Therapeutics (NasdaqGM:CRSP) is set to participate in several major healthcare ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. CRISPR ...

The big shareholder groups in CRISPR Therapeutics AG (NASDAQ:CRSP) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders ...

Jack has a degree in Medical Genetics from the University of Leicester.View full profile Jack has a degree in Medical Genetics from the University of Leicester. The first CRISPR gene-edited food has ...